Grünenthal receives Brazilian ANVISA certification for Tecnandina production plant in Ecuador

5 October 2015
grunenthal-big

Family-owned German drugmaker Grünenthal Group says that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil, ANVISA. This will allow Tecnandina to export pharmaceutical products also to Brazil and makes it the first production plant in Ecuador to receive ANVISA certification.

“We are very pleased that our plant in Ecuador can now also be a full service supply partner for Brazil as it is already for Andean countries and the Mexican market. The ANVISA certification is another key milestone in demonstrating our high quality capabilities in global contract manufacturing,” states Alberto Grua, a member of the corporate executive board of Grünenthal.

The Grünenthal Group offers contract manufacturing from its five independent production plants throughout Europe and Latin America.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics